Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab.1976;42:222-229.
2.
UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes.1995;44:1249-1258.
3.
Ryan EA, Imes S., Wallace C.Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27: 1028-1032.
4.
Alvarsson M. , Sundkvist G., Lager I., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003 ;26:2231-2237.
5.
Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27:2597-2602.
6.
Colagiuri S. , Cull CA, Holman RR; UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?Diabetes Care. 2002;25:1410-1417.
7.
Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RRGlycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care.2005;28:995-1000.
8.
DeFronzo RA, Goodman AMEfficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med.1995;333:541-549.
9.
Fonseca V., Rosenstock J., Patwardhan R., Salzman A.Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA.2000;283:1695-1702.
10.
Kipnes MS, Krosnick A., Rendell MS, Egan JW, Mathisen AL, Schneider RLPioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med.2001;111:10-17.
11.
Rosenstock J., Sugimoto D., Strange P., Stewart JA, Soltes-Rak E., Dailey G.Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554-559.
12.
Brown JB, Nichols GA, Perry A.The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
13.
Riddle MC, Rosenstock J., Gerich J.The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care . 2003;26:3080-3086.
14.
Janka HU, Plewe G., Riddle MC, Kliebe-Frisch C., Schweitzer MA, Yki-Jarvinen H.Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
15.
Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
16.
Riddle MCThe underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18(suppl 3):S42-S49.
17.
Aviles-Santa L., Sinding J., Raskin P.Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med.1999;131:182-188.
18.
Yki-Jarvinen H., Ryysy L., Nikkila K., Tulokas T., Vanamo R., Heikkila M.Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med.1999;130:389-396.
19.
Bergenstal R. , Johnson M., Whipple D., et al. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes. Diabetes . 1998;47(suppl 1):A89.
20.
Dandona P., Aljada A., Chaudhuri A., Bandyopadhyay A.The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes . J Clin Endocrinol Metab.2003;88:2422-2429.
21.
Malmberg K. , Ryden L., Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year . J Am Coll Cardiol.1995;26:57-65.
22.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet.1998; 352:854-865.
23.
Van denBerghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med.2001;345: 1359-1367.
24.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and theEuropean Association for the Study of Diabetes. Diabetes Care.2006;29:1963-1972.
25.
The American Diabetes Association.2007resource guide: a supplement to Diabetes Forecast. Insulins; RG13-RG18. Diabetes Forecast. Available at: http://www.diabetes.org/diabetes-forecast/RG07/RG07Insulin.pdf . Accessed January 11, 2007.
26.
Bretzel RG, Linn T.Equivalence of basal insulin glargine vs prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents—results of the APOLLO study. Diabetes.2006; 55(suppl 1):A76. Abstract 326-OR.
27.
Kazda C., Hulstrunk H., Helsberg K., Langer F., Forst T., Hanefeld M.Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat.2006;20:145-152.
